Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith S Kaye

Showing results (121-130 of 421) with videos related to

Pageof 43
Sort By:
Future Microbiology|March 1, 2024
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting <i>Acinetobacter baumannii</i>Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, et al.
Pharmacotherapy|March 7, 2012
Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohortRavina Kullar, Susan L Davis, Thomas N Taylor, et al.
Emerging Infectious Diseases|April 14, 2004
Fluoroquinolones protective against cephalosporin resistance in gram-negative nosocomial pathogensMitchell J Schwaber, Sara E Cosgrove, Howard S Gold, et al.
Infection Control and Hospital Epidemiology|January 21, 2014
Readmissions after diagnosis of surgical site infection following knee and hip arthroplastyKyle G Miletic, Thomas N Taylor, Emily T Martin, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 29, 2006
Risk factors for 1-year mortality after postoperative mediastinitisRavi Karra, Lisa McDermott, Sarah Connelly, et al.
Infection Control and Hospital Epidemiology|July 10, 2004
Surgical-site infection due to Staphylococcus aureus among elderly patients: mortality, duration of hospitalization, and costSarah A McGarry, John J Engemann, Kenneth Schmader, et al.
Infection Control and Hospital Epidemiology|January 4, 2008
Measuring acceptable treatment failure rates for community-acquired pneumonia: potential for reducing duration of treatment and antimicrobial resistanceKeith S Kaye, Anthony D Harris, Jay R McDonald, et al.
Infection and Drug Resistance|September 27, 2018
Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant <i>Enterobacteriaceae</i>Lindsay A Petty, Oryan Henig, Twisha S Patel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitalsKeith S Kaye, Deverick J Anderson, Yong Choi, et al.
Diagnostic Microbiology and Infectious Disease|November 7, 2018
Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utilityThamer A Almangour, Gregory K Perry, Colleen M Terriff, et al.
Pageof 43

Showing results (121-130 of 421) with videos related to

Sort By:
Pageof 43
Future Microbiology|March 1, 2024
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting <i>Acinetobacter baumannii</i>Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, et al.
Pharmacotherapy|March 7, 2012
Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohortRavina Kullar, Susan L Davis, Thomas N Taylor, et al.
Emerging Infectious Diseases|April 14, 2004
Fluoroquinolones protective against cephalosporin resistance in gram-negative nosocomial pathogensMitchell J Schwaber, Sara E Cosgrove, Howard S Gold, et al.
Infection Control and Hospital Epidemiology|January 21, 2014
Readmissions after diagnosis of surgical site infection following knee and hip arthroplastyKyle G Miletic, Thomas N Taylor, Emily T Martin, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 29, 2006
Risk factors for 1-year mortality after postoperative mediastinitisRavi Karra, Lisa McDermott, Sarah Connelly, et al.
Infection Control and Hospital Epidemiology|July 10, 2004
Surgical-site infection due to Staphylococcus aureus among elderly patients: mortality, duration of hospitalization, and costSarah A McGarry, John J Engemann, Kenneth Schmader, et al.
Infection Control and Hospital Epidemiology|January 4, 2008
Measuring acceptable treatment failure rates for community-acquired pneumonia: potential for reducing duration of treatment and antimicrobial resistanceKeith S Kaye, Anthony D Harris, Jay R McDonald, et al.
Infection and Drug Resistance|September 27, 2018
Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant <i>Enterobacteriaceae</i>Lindsay A Petty, Oryan Henig, Twisha S Patel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2008
The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitalsKeith S Kaye, Deverick J Anderson, Yong Choi, et al.
Diagnostic Microbiology and Infectious Disease|November 7, 2018
Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utilityThamer A Almangour, Gregory K Perry, Colleen M Terriff, et al.
Pageof 43